Related Experiment Video
Updated: Jun 30, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Sunitinib-induced acute hemolysis without hypertension: a case report
Rajul Jain1, Paul Mathew, Christopher G Wood
1Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Sunitinib can cause blood problems like low white blood cells. This case shows sunitinib can also cause severe hemolysis, a red blood cell issue, which resolved after stopping the drug.
Area of Science:
- Oncology
- Pharmacology
Background:
- Sunitinib is a tyrosine kinase inhibitor used for metastatic renal cell carcinoma.
- Hematologic adverse events are common side effects of sunitinib therapy.
Observation:
- A patient with metastatic renal cell carcinoma developed severe hemolysis.
- This complication occurred during treatment with sunitinib.
- The patient did not exhibit concurrent hypertension or reversible posterior leukoencephalopathy syndrome.
Findings:
- Sunitinib can induce severe hemolysis, a rare but serious adverse event.
- Discontinuation of sunitinib led to the resolution of hemolysis.
- Hemolysis is a distinct adverse event from other known sunitinib-associated hematologic toxicities.
Implications:
- Clinicians should be vigilant for hemolysis as a potential sunitinib adverse event.
- Early recognition and discontinuation of sunitinib may prevent severe complications.
- This case expands the understanding of sunitinib's hematologic toxicity profile.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Hemodialysis II: Procedure and Complications
Antihypertensive Drugs: Potassium-Sparing Diuretics

